Diagonal Bio logo

Diagonal Bio Investor Relations Material

Diagonal Bio AB operates as a biotechnology company in Sweden. The company is focused on the development of drug candidate for treatment of diabetes and obesity, based on its technology for targeting the GLP-1 receptor. The company also develops small molecules for pharmaceutical and diagnostic purposes. It offers DiabNext, which is in Phase II trial for dibenzo-p-dioxin (DCDX)-induced significant reduction in pulmonary hypertension syndrome (PH). The company is based in Lund, Sweden.

Upcoming events for

Q2 20222022-08-23

Latest company events

More about Diagonal Bio

Ticker symbol

DIABIO

Country

Sweden

About the company

https://diagonalbio.com/

Investor Relations Page

https://diagonalbio.com/investors/

Dig deeper into the Diagonal Bio fundamentals on Quartr.

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
App store link
Android play link
Quartr app screenshot